Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical is a medical company developing novel pharmaceutical solutions for large unmet needs using the development pathway. The company focused on improving clinical outcomes for patients battling opioid use disorder, viral respiratory infections from coronaviruses such as COVD-19 and other painful inflammation and toxin-induced conditions, including arthritis, vaccinations, and even the infamous hangover.

Sen-Jam Pharmaceutical develops consumer healthcare products that help people stay strong by mitigating common side effects from medicines and everyday living. The company global scientists have developed a multi-indication patent and FDA-pending product for the prevention of pain and flu-like symptoms for indications not currently being addressed by the FDA OTC Drug Monograph.

We developed an innovative anti-inflammatory portfolio of products that we believe will revolutionize pain relief in an accessible, affordable, and scalable way. The first 3 applications include oral COVID-19 therapeutic, opioid withdrawal relief, & hangover prevention. All three are on an accelerated 505(b)(2) regulatory pathway with the FDA, and we believe we will be able to sell or license all 3 applications by 2025.

We’ve raised $3.1M to date, and we’re accepting investors to join us on our mission as we advance these revolutionary solutions to market.

$3.1 million